전이성 거세저항성 전립선암(mCRPC) : 세계 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(주요 32 시장) - 2025-2035년

Global Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook

Thelansis's "Global Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential mCRPC treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview

Metastatic Castration-Resistant Prostate Cancer (mCRPC) represents an advanced and aggressive stage of prostate cancer characterized by disease progression despite castrate levels of testosterone achieved through androgen deprivation therapy. The condition is driven by persistent androgen receptor signaling and alternative resistance mechanisms, enabling continued tumor growth and metastatic spread.

Clinically, mCRPC predominantly metastasizes to bone and lymph nodes, leading to significant complications such as bone pain, fractures, spinal cord compression, and systemic symptoms including fatigue and functional decline. These manifestations substantially impact patient quality of life and contribute to high morbidity.

The current treatment landscape is multifaceted, incorporating next-generation androgen receptor pathway inhibitors, chemotherapy, radiopharmaceuticals, and supportive care. While these therapies have improved overall survival, treatment resistance and disease progression remain inevitable for most patients, highlighting the limitations of existing options. Consequently, mCRPC remains a major focus of oncology innovation, with ongoing development of targeted therapies, immunotherapies, radioligand therapies, and combination strategies aimed at improving durability of response and personalizing treatment approaches.

Key Highlights

• In Italy, the diagnosed mCRPC patient pool is projected to increase from 37.5K in 2025 to 39.4K by 2035, indicating modest growth (0.5% CAGR) driven by aging population and improved survival.
• Disease progression and therapeutic resistance remain key challenges, with most patients eventually exhausting available treatment options.
• Increasing focus on precision oncology, radioligand therapies, and combination treatment strategies is expected to significantly evolve the future treatment landscape.

Market Overview

• The Germany mCRPC market is projected to grow from $342M in 2025 to $538M by 2035, reflecting steady growth driven by continued adoption of novel oncology therapies.
• Market expansion is supported by:
• Uptake of next-generation androgen receptor inhibitors and radiopharmaceuticals
• Increasing use of combination and sequential treatment strategies
• Despite relatively modest patient growth (0.5% CAGR), market growth is driven by high-value therapies and extended treatment duration.
• Future growth will depend on the successful integration of precision medicine approaches and novel modalities that improve survival outcomes and delay resistance.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Bristol-Myers Squibb
• K36 Therapeutics, Inc.
• Janux Therapeutics
• Janssen Pharmaceutical
• Celgene
• AstraZeneca
• POINT Biopharma
• Amgen
• TechnoGenesys, Inc.
• Pfizer
• Merck Sharp & Dohme LLC
• Daiichi Sankyo
• Aragon Pharmaceuticals, Inc.
• AbbVie
• BioNTech SE
• Hoffmann-La Roche
• Fusion Pharmaceuticals Inc.
• Syncromune, Inc.
• Astellas Pharma Global Development, Inc.
• Arsenal Biosciences, Inc.
• Atridia Pty Ltd.
• Shanghai AbelZeta Ltd.
• Regeneron Pharmaceuticals
• Bayer
• Novartis Pharmaceuticals
• Tasly Pharmaceutical Group Co., Ltd
• Blue Earth Therapeutics Ltd
• Inmune Bio, Inc.
• Celcuity Inc
• Pathos AI, Inc.
• IntoCell, Inc
• Orano Med LLC
• Nuvation Bio Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)